These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 31734955)

  • 61. The introduction of a targeted user-pays approach to funding high-level residential aged care in Australia: an empirical investigation of the impact on price.
    Gargett S
    Health Econ Policy Law; 2010 Oct; 5(4):481-508. PubMed ID: 20122304
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Multi stakeholders of health and industries perspectives on medicine price transparency initiative in private health care settings in Malaysia.
    Sufiza Ahmad N; Makmor-Bakry M; Hatah E
    Saudi Pharm J; 2020 Jul; 28(7):850-858. PubMed ID: 32647487
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Effects of asymmetric medical insurance subsidy on hospitals competition under non-price regulation.
    Wang C; Nie PY
    Int J Equity Health; 2016 Nov; 15(1):184. PubMed ID: 27846902
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Doctors dropping Medicare patients.
    Freudenheim M
    N Y Times Web; 1992 Apr; ():1, 26. PubMed ID: 11647927
    [No Abstract]   [Full Text] [Related]  

  • 65. Availability of consumer prices from US hospitals for a common surgical procedure.
    Rosenthal JA; Lu X; Cram P
    JAMA Intern Med; 2013 Mar; 173(6):427-32. PubMed ID: 23400757
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Combining the best of two medical worlds: Canadian universality and United States' freedom.
    Benjamin WW
    Humane Med; 1992 Oct; 8(4):271-85. PubMed ID: 11651423
    [No Abstract]   [Full Text] [Related]  

  • 67. Reforming Britain's National Health Service: an application of Engelhardtian justice.
    Kessel R
    Bus Prof Ethics J; 1990; 9(3 and 4):121-32. PubMed ID: 11651032
    [No Abstract]   [Full Text] [Related]  

  • 68. Methods for the comparative evaluation of pharmaceuticals.
    Zentner A; Velasco-Garrido M; Busse R
    GMS Health Technol Assess; 2005 Nov; 1():Doc09. PubMed ID: 21289930
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The Experience and Effectiveness of Nurse Practitioners in Orthopaedic Settings: A Comprehensive Systematic Review.
    Taylor A; Staruchowicz L
    JBI Libr Syst Rev; 2012; 10(42 Suppl):1-22. PubMed ID: 27820153
    [TBL] [Abstract][Full Text] [Related]  

  • 70. How Price Regulation Is Needed To Advance Market Competition.
    Berenson RA; Murray RB
    Health Aff (Millwood); 2022 Jan; 41(1):26-34. PubMed ID: 34982623
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Medicare to weigh cost as a factor in reimbursement.
    Pear R
    N Y Times Web; 1991 Apr; ():1, 26. PubMed ID: 11646853
    [No Abstract]   [Full Text] [Related]  

  • 72. Confidentiality agreements: a challenge in market regulation.
    Iunes RF; Uribe MV; Torres JB; Garcia MM; Dias CZ; Alvares-Teodoro J; de Assis Acurcio F; Guerra-Junior AA
    Int J Equity Health; 2019 Jun; 18(1):11. PubMed ID: 31155003
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Lessons from game theory about healthcare system price inflation: evidence from a community-level case study.
    Agee MD; Gates Z
    Appl Health Econ Health Policy; 2013 Feb; 11(1):45-51. PubMed ID: 23329381
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Why is there a quality chasm?
    Newhouse JP
    Health Aff (Millwood); 2002; 21(4):13-25. PubMed ID: 12117124
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Annual expenditures for nursing home care: private and public payer price growth, 1977 to 2004.
    Stewart KA; Grabowski DC; Lakdawalla DN
    Med Care; 2009 Mar; 47(3):295-301. PubMed ID: 19194339
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Barriers to Price and Quality Transparency in Health Care Markets.
    Rao P; Fischer SH; Vaiana ME; Taylor EA
    Rand Health Q; 2022 Jun; 9(3):1. PubMed ID: 35837511
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Cutting waste by making rules: promises, pitfalls, and realistic prospects.
    Blustein J; Marmor TR
    Univ PA Law Rev; 1992 May; 140(5):1543-72. PubMed ID: 11651591
    [No Abstract]   [Full Text] [Related]  

  • 78. External referencing and pharmaceutical price negotiation.
    Garcia Mariñoso B; Jelovac I; Olivella P
    Health Econ; 2011 Jun; 20(6):737-56. PubMed ID: 20577969
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Eliminating drug price differentials across government programmes in the USA.
    Chalkidou K; Anderson GF; Faden R
    Health Econ Policy Law; 2011 Jan; 6(1):43-64. PubMed ID: 20128956
    [TBL] [Abstract][Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.